Singapore, March 25 -- The Health Sciences Authority received information related to the study titled 'A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
National University Hospital
Trial Status: Ongoing, Recruiting
Principal Investigator(s):
Dr Robert John Walsh
Published by HT Digital Content Services with permission from Health Daily Digest....